World Renowned Eye Expert Dr. José-Alain Sahel, M.D. Joins Advisory Board of Ichor Therapeutics, Inc.

Will Advise on Clinical Trial Design for Dry AMD and Stargardt’s Treatment LaFayette, NY – Ichor Therapeutics, Inc. (Ichor Therapeutics) is pleased to announce that it has recruited one of the world’s top experts in retinal disease, Dr. José-Alain Sahel, M.D., to join its Advisory Board regarding LYSOCLEAR™, a pre-clinical drug candidate in development by its affiliate, Lysoclear, Inc. (Lysoclear),

Read more


Centerstate CEO President Links Onondaga Lake’s Troubled Past to “Pervasive Pessimism” in CNY

Onondaga Lake marked a major milestone this week when dredging and capping operations were declared complete. As recently as 15 years ago, and as far back as a century, many felt the lake and its habitat would never be restored after decades of industrial pollution. Centerstate CEO President Rob Simpson says that cynicism has persisted as a metaphor for the

Read more


Dr. William Gannon Joins the Ichor Science Advisory Board.

Ichor Therapeutics, a pre-clinical biotechnology company located in Syracuse, NY focused on therapeutic interventions for age-related disease, is pleased to announce the addition of William E. Gannon, Jr., MD to the Ichor Science Advisory Board. Dr. Gannon will be advising Ichor on clinical development planning and FDA compliance. His background managing clinical trials and operations as well as the design

Read more


CNY research startup raises $3.2 million to develop treatment for vision loss

By Elizabeth Doran |  LAFAYETTE, NY Inside a laboratory tucked in the LaFayette hills south of Syracuse, a small biotech company is quietly developing drugs that may show promise to treat, prevent and possibly even reverse macular degeneration, a disease that’s a leading cause of vision loss. The new drug therapies being developed and tested are designed to work on

Read more


Methuselah Foundation Fellowship Award Winner Tackles Research in Macular Degeneration

Typically, a fellowship and participation in a research study to cure a major disease would occur years after completing undergrad, possibly even after earning a PhD. But Jennifer DeRosa is not a typical student.  As early as high school, DeRosa was already in the lab, conducting research in plant biotechnology at the College of Environmental Science and Forestry (SUNY-ESF) before

Read more


Ichor nabs $600,000 program investment and new partnerships in wake of company expansion and promising early results

Ichor nabs $600,000 program investment and new partnerships in wake of company expansion and promising early results   Ichor builds new partnerships and lands $600k investment for its Age-related Macular Degeneration (AMD) research initiative, which has shown positive early results. Age-related Macular Degeneration (AMD) is a presently incurable eye condition leading to partial loss of vision and affects as many

Read more


Dr. Bärbel Rohrer Joins Ichor Therapeutics’ Scientific Advisory Board

LaFayette, NY, June 20, 2016 –  Ichor Therapeutics, Inc a biotech contract research firm specializing in age-related diseases, adds Dr. Bärbel Rohrer to their scientific advisory board. Dr. Rohrer will assist with the design and execution of pivotal animal studies for Ichor’s therapeutic candidates for age-related macular degeneration. “Dr. Rohrer is an addition of incredible value to our advisory team.”

Read more


GLP/GMP is next for Ichor Therapeutics.

In March we signed on a new investor, Roger Bagg (you may have seen our press release over at MedTech, or the Town of Lafayette Newsletter – we’re glad everyone else was as excited as we were!). Roger is an ideal investor for Ichor. He has experience investing in other Biotech firms both in the US and the UK, and philosophically

Read more